The Documentation Burden: When Clicking Boxes Competes With Patient Care

Read the article here: https://oncdata.com/how-clinical-intuition-and-genomic-ai-solved-a-cancer-misdiagnosis-mystery Artificial intelligence (AI) is creating new opportunities to identify the origins of cancer, particularly when a diagnosis does not fit the clinical picture. In this episode of Exploring AI in Oncology, Dr. Vitor Pastorini, a Medical Oncologist at Florida Oncology and Hematology, and Dr. George Sledge, Chief Medical Officer at Caris Life Sciences and former Chief of Oncology at Stanford University, sit down with Dr. Waqas Haque to discuss how AI-enabled genomic profiling can help reassess tumor origin. Through the case of a patient whose presumed metastatic breast cancer was ultimately identified as Hodgkin lymphoma, they explore the potential of genomic prediction tools, the importance of confirming unexpected results with additional testing and expert review, and the role of clinical judgment in ensuring patients receive the right diagnosis and treatment.

Read the full article here! https://oncdata.com/oncology-unfiltered-the-documentation-burden Electronic health records (EHRs) and digital workflows were conceived to modernize and streamline cancer care, but for clinicians practicing on the ground, administrative demands have ballooned into an overwhelming daily burden. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Editor in Chief Matthew Hadfield, DO, Medical Oncologist and Assistant Professor of Medicine at Brown University Legorreta Cancer Center, to explore the personal, clinical, and operational ramifications of modern medical documentation. Together, they examine how health systems can return clinical attention to where it belongs: direct, compassionate patient care.

Read the full article here: https://oncdata.com/reimagining-oncology-education-with-ai New clinical trials, guideline updates, therapeutic approaches, and diagnostic technologies are continually reshaping how oncology clinicians learn and practice. For trainees preparing for board examinations and practicing clinicians seeking to stay current, conventional tools are not always sufficient to keep pace with the speed and volume of information. In this episode of Exploring AI in Oncology, Dr. Roupen Odabashian, Medical Oncologist at Abbotsford Regional Hospital, shares his path from hematology/oncology fellowship to building MeducationAI, an AI-enabled learning platform for cancer care professionals. His conversation with Dr. Waqas Haque explores the accelerating pace of oncology knowledge, the need for human oversight in AI-supported education, and how clinicians can develop practical AI literacy.

Read the full article here: https://oncdata.com/personalizing-surgical-risk-assessment-in-lung-cancer For many patients with lung cancer, surgery offers the best chance for cure and long-term survival, but that opportunity can come with meaningful risk—particularly for older patients with smoking histories, reduced lung function, frailty, or other medical conditions. In this episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Dr. Kenneth Patrick Seastedt, Thoracic Surgeon at Roswell Park Comprehensive Cancer Center, about MIRACLE, an AI-enabled platform designed to help predict postoperative pulmonary complications after lung cancer surgery. By combining clinical data, radiomic information extracted from CT imaging, and large language model (LLM)–generated risk explanations, the platform creates a more personalized assessment of surgical risk—all while keeping surgeons involved in every stage of interpretation and decision making.

Check out the full article at: https://oncdata.com/oncology-unfiltered-clinical-trial-enrollment-barriers While clinical trials represent the cutting edge of modern cancer therapy, significant disparities persist in determining who actually enrolls in them. In this episode of Oncology Unfiltered, Melissa Cotrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sat down with Editor in Chief Matthew Hadfield, DO, Medical Oncologist and Assistant Professor of Medicine at Brown University Legorreta Cancer Center, to unpack the practical, structural, and clinical hurdles that prevent eligible patients from accessing potentially lifesaving investigational therapies. Together, they explore how the oncology community can translate trial availability into meaningful access.

Read the full article at: https://oncdata.com/real-world-evidence-ai-in-oncology Artificial intelligence (AI) is rapidly transforming oncology research, but its impact depends on high-quality data. As researchers increasingly rely on real-world evidence (RWE) to complement clinical trials, ensuring that data is accurate, complete, and transparent has become just as important as developing new AI tools. In this episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Saamir Pasha, Senior Biostatistician at Ontada, about two complementary areas of innovation—the establishment of rigorous frameworks to assess the quality of oncology real-world data, and the exploration into how generative AI can accelerate complex biostatistical workflows while maintaining scientific rigor and regulatory transparency. Together, these efforts illustrate how AI is poised to enhance—not replace—the expertise required to generate reliable evidence in oncology.

Read the full article at: https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.

Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains inconsistent. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights the critical shift that is moving AI from theoretical promise to practical application.

Are you treating extrapulmonary neuroendocrine carcinomas based on where they start—or what they actually are? In this faculty follow-up to their i3 Health activity (Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets), Andrew Hendifar, MD, and Danielle Hutchings, MD (Cedars-Sinai Medical Center), unpack why treating these rare, aggressive tumors according to site of origin rather than tumor lineage can compromise outcomes. They clarify crucial pathologic distinctions between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) while emphasizing the essential role of multidisciplinary collaboration in precision care. The experts also explore the novel therapeutic landscape of delta-like ligand 3 (DLL3)–targeted therapies, highlighting the promise of DLL3 T-cell engagers in extrapulmonary disease. They address ongoing diagnostic hurdles—such as standardized immunohistochemistry (IHC) expression thresholds and expanding send-out testing access—while sharing key insights on emerging clinical trials evaluating T-cell engager monotherapies and chemo-immunotherapy combinations. Claim your CME credit: bit.ly/488fPhK Download and review the companion Clinical Challenges in Extrapulmonary NEC Slide Deck: bit.ly/4w2Pni3

What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies? In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO that is actively reshaping care algorithms across the prostate cancer continuum. Dr. Freedland dives into the breakthrough TALAPRO-3 trial—exploring why talazoparib plus enzalutamide is making waves across diverse HRR alterations (including BRCA and ATM)—and analyzes how the PROTEUS trial’s 35% reduction in subsequent salvage therapies could redefine surgical planning for high-risk localized disease. Plus, get an insider's look at what’s on the horizon with PSMA PET imaging, T-cell engagers, and AR degraders. 🎓Complete the Educational Activity: https://bit.ly/4x2BnWf